Incomplete Success of Angioinhibitor Therapy in Cancer: Estimation of Contribution of Pro-angiogenic Activity of Patient Thyroid Hormone
- *Corresponding Author:
- Paul J Davis, M.D.
Pharmaceutical Research Institute
Albany College of Pharmacy and Health Sciences
One Discovery Drive, Rensselaer, NY 12144, USA
Tel: 518 428 7848
Fax: 518 694 7567
E-mail: [email protected]
Received Date: November 01, 2013; Accepted Date: December 26, 2013; Published Date: December 30, 2013
Citation: Davis PJ, Yalcin M, Lin HY, Tang HY, Hercbergs A, et al. (2013) Incomplete Success of Angioinhibitor Therapy in Cancer: Estimation of Contribution of Proangiogenic Activity of Patient Thyroid Hormone. J Cancer Sci Ther 5:441-445. doi: 10.4172/1948-5956.1000238
Copyright: © 2013 Davis PJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Despite the obvious promise of the strategy, pharmaceutical angioinhibition has had variable success in clinical cancer management. Thyroid hormone is a potent pro-angiogenic factor. Endogenous circulating levels of proangiogenic thyroid hormone in cancer patients treated with anti-angiogenic drugs may contribute to host resistance to angioinhibition and explain, at least in part, the variable cancer chemotherapeutic responses obtained with anti-angiogenic agents. The chick chorioallantoic membrane (CAM) angiogenesis assay accepts human tumor xenografts and is a system in which individual patient blood samples can be tested in xenograft vasculature for anti-angiogenic content—including thyroid hormone—in the presence of angioinhibitory drug dose escalation. The assay may also be used to screen individual patient tumor biopsy xenografts for susceptibility to angioinhibition.